Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds
Research ArticlePractical Protocol Tips

18F-Fluciclovine

Jason Colloton
Journal of Nuclear Medicine Technology December 2019, 47 (4) 267-268; DOI: https://doi.org/10.2967/jnmt.119.236141
Jason Colloton
CNMT, RT(N)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

CLINICAL INDICATIONS

18F-fluciclovine (Axumin; Blue Earth Diagnostics) is an amino acid analog indicated for PET in men with suspected recurrent prostate cancer based on an elevated level of prostate-specific antigen (PSA) after prior treatment (4).

CONTRAINDICATIONS

None.

PATIENT EDUCATION AND PREPARATION

Before Arrival in PET/CT Department

  • Allow the patient to take prescribed medications with small sips of water.

  • Instruct the patient not to take any food or water by mouth for at least 4 h before receiving the 18F-fluciclovine injection.

  • Instruct the patient to avoid significant strenuous exercise for 24 h before receiving the 18F-fluciclovine injection.

  • Instruct the patient to avoid voiding the urinary bladder for at least 1 h before receiving the 18F-fluciclovine injection and undergoing imaging.

On Arrival in PET/CT Department

  • Obtain a focused history of past and current diseases, interventional or surgical procedures, and medications.

  • Obtain and document the patient’s height and weight.

  • Educate the patient in detail about the procedure, including time to completion, required position for imaging (supine), and voiding restrictions.

  • Evaluate the patient’s ability to lie still for up to 30 min.

PROTOCOL AND ACQUISITION

  • Unless contraindicated, place an intravenous catheter in the right arm (avoids possible uptake in the Virchow lymph node in the left supraclavicular fossa, should any portion of the dose be infiltrated), and verify patency with a normal-saline flush (1,3).

  • Position the patient supine on the imaging table, with the arms above the head.

  • Evaluate patient comfort, emphasizing to the patient the importance of remaining still.

  • Perform a scout CT view.

  • Plan the CT and PET region to be from skull base to mid thigh, with the prostate bed centered in the first bed position.

  • Acquire a CT scan from upper mid thigh to skull base for anatomic correlation and attenuation correction, per site standards, before assaying the patient dose. Refer to the manufacturer’s recommendations for the CT acquisition parameters.

  • Move the patient into position for the PET scan, and prepare for the scan but do not start it (Table 1) (2).

  • Prepare and calibrate the recommended dose (370 MBq [10 mCi] ± 20%), inject it intravenously (with the patient’s arms down) over a period of 5–10 s, and follow it by a 10-mL saline flush.

  • Begin imaging within 3–5 min after injection (with a goal of 4 min).

View this table:
  • View inline
  • View popup
TABLE 1

Standard PET Acquisition Parameters

PROCESSING

  • Review raw data for motion.

  • Use 18F-FDG reconstruction parameters (iterative reconstruction is most often used, and the gaussian filter should not exceed 5 mm).

  • Refer to the manufacturer’s guidelines for emission-data reconstruction protocols that correct for detector efficiency (normalization), system dead time, random coincidences, scatter attenuation, and sampling nonuniformity.

  • Create non–attenuation-corrected and attenuation-corrected images.

  • Appropriately scale data and display in transaxial, coronal, and sagittal planes and as a rotating maximum-intensity-projection image.

REFERENCES

  1. 1.
    1. Tade F,
    2. Sajdak RA,
    3. Gabriel M,
    4. Wagner RH,
    5. Sabir-Baruch B
    . Best Practices of 18F-fluciclovine PET/CT imaging for recurrent prostate cancer: a guide for technologists. J Nucl Med Technol. June 10, 2019 [Epub ahead of print].
  2. 2.↵
    1. Farrell MB,
    2. Mantel ES,
    3. Basso DA,
    4. Thomas KS,
    5. Kerr BR
    . PET: whole body imaging—18F-FDG. In: Quick Reference Protocol Manual for Nuclear Medicine Technologists. Reston, VA: Society of Nuclear Medicine and Molecular Imaging; 2014:271–274.
  3. 3.
    1. Mantel ES,
    2. Williams J
    . F-18 fluciclovine: part of your imaging arsenal. Uptake. 2017;23(1):1, 7.
    OpenUrl
  4. 4.↵
    Axumin (18F-fluciclovine) [prescribing information]. Oxford, UK: Blue Earth Diagnostics Ltd.; 2016.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 47 (4)
Journal of Nuclear Medicine Technology
Vol. 47, Issue 4
December 1, 2019
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
18F-Fluciclovine
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
18F-Fluciclovine
Jason Colloton
Journal of Nuclear Medicine Technology Dec 2019, 47 (4) 267-268; DOI: 10.2967/jnmt.119.236141

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
18F-Fluciclovine
Jason Colloton
Journal of Nuclear Medicine Technology Dec 2019, 47 (4) 267-268; DOI: 10.2967/jnmt.119.236141
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • CLINICAL INDICATIONS
    • CONTRAINDICATIONS
    • PATIENT EDUCATION AND PREPARATION
    • PROTOCOL AND ACQUISITION
    • PROCESSING
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • 2019: A Year of Reflection
  • 2019: A Year of Reflection
  • Google Scholar

More in this TOC Section

  • 223Ra-Dichloride Therapy
  • 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy
  • 18F-FDG PET/CT Brain Imaging
Show more Practical Protocol Tips

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire